There has been a lot of discussion in this forum about the pros and cons of hydroxychloroquine use, so what do doctors who are treating patients think? An American Thoracic Society‐led International Task Force recently issued "Interim Guidance on Management Pending Empirical Evidence" on treatments such as hydroxychloroquine and remdesivir.
Wrestling with the question of whether to recommend covid-19 treatments with imperfect evidence, they "suggest" use of hydroxychloroquine in hospitalized patients who have evidence of pnemonia on a case-by-case basis, but don't recommend routine use for covid-19 patients.
The recommendations were based on a survey of members who were working on the frontlines treating covid-19.
73% were in favor of intervention, 11% against, and 16% no suggestion.
"For hospitalized patients with COVID‐19 who have evidence of pneumonia, we suggest hydroxychloroquine (or chloroquine) on a case‐by‐case basis. Requirements include all of the following: a) shared decision‐making in which the patient is informed about the possible benefits and potential side effects, b) collection of data in a manner that enables studies that use valid methods for causal inference and control of confounders for the purpose of interim assessment, c) the patient’s clinical condition is sufficiently severe to warrant investigational therapy, and d) there is not a shortage of drug supply."
Interestingly, the Task Force did not "suggest" use of remdesivir even in hospitalized patients with evidence of pneumonia. Support for that option fell slightly below its somewhat arbitrary 70% cut-off needed for a "suggestion." I suspect this will change after the results of the most recent remesdivir data are factored in.
https://www.thoracic.org/profession...sease-related-resources/covid-19-guidance.pdf